Failure to Follow Professional Standards After Discontinuation of Statin Therapy
Summary
The deficiency involves the facility’s failure to meet professional standards of quality in managing a statin medication for Resident 1. The resident was admitted with multiple cardiovascular diagnoses, including hypertensive heart disease with heart failure and combined systolic and diastolic heart failure, and had a documented diagnosis of hyperlipidemia. The admission orders included Atorvastatin 20 mg by mouth at bedtime for hyperlipidemia. The resident’s MDS showed moderately impaired cognitive skills for daily decision making and dependence on staff for several ADLs. A Drug Regimen Review dated 4/4/2026 documented an allergy to Simvastatin and questioned whether the resident could tolerate Atorvastatin. On 4/6/2026, the physician discontinued Atorvastatin. The DON later stated that the DRR did not indicate that Atorvastatin should be stopped, only that there was a question about tolerance due to the Simvastatin allergy, and acknowledged that Atorvastatin was usually not abruptly stopped. The RN Supervisor confirmed that Atorvastatin was discontinued on 4/6/2026 and stated that, after stopping cholesterol medications, staff should contact the physician for laboratory orders to determine baseline levels and to ask if a new order is needed to replace the discontinued medication. The RN Supervisor stated there was no follow-up after Atorvastatin was discontinued and that the necessary follow-up had “gone through the cracks.” The consultant pharmacist stated that when there is a possible cross allergy, licensed nurses should not wait to contact the physician to switch the medication and that the medication should not just be discontinued because of a possible cross allergy without clarifying the plan. Facility policies required licensed nurses to verify medications and directions for use with physician orders and promptly report discrepancies and omissions, and required staff to provide services in compliance with laws, regulations, and professional standards. The failure to follow up with the physician regarding alternative therapy and laboratory monitoring after discontinuation of Atorvastatin constituted the deficient practice.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.